Chronic pain is difficult to treat and affects the individual’s quality of life, often leading to severe disability. Ketamine was initially used in anaesthesia, but since the 1990s it has also been used in a much lower dose as a treatment for acute and chronic pain. and also works as an antidepressant
Professor Albert Dahan and colleagues at the Leiden University Medical Center managed to unlock some of ketamine’s previously unknown mechanisms of action against pain, its psychedelic effects, and also new actions on the heart and breathing mechanism.
Read the original research: https://doi.org/10.1097/ALN.0000000000004176
Read more in Research Outreach
Image source: Thaiview/Shutterstock
Hello and welcome to Research Pod! Thank you for listening and joining us today.
In this episode, we will be looking at the work of Professor Albert Dahan from the Leiden University Medical Center in the Netherlands, who is studying a controversial and often overlooked drug called ketamine. Dahan considers the drug for its role in chronic pain management and mood disorders, and regulating heart function and breathing, which could be transformative in developing new treatments.
Chronic pain is defined as pain that lasts longer than three months or longer than the expected healing time after an injury or surgery. However, chronic pain is not just pain secondary to an injury that hasn’t yet healed; the mechanisms behind it are much more complex. It occurs when the nervous system responds in unusual ways that don’t accurately reflect what is going on inside the body. This can be explained by a persistent state of reactivity of the nervous system, even after the initial area of damage heals. In a vicious circle, pain causes the nervous system to be more alert – or excited – and the alertness itself leads to more sensitivity to various stimuli and pain. Chronic pain is difficult to treat and affects the individual’s quality of life, often leading to severe disability. So, how are clinicians meant to manage patient’s pain?
There are different types of chronic pain, including Complex Regional Pain Syndrome Type 1, or CRPS-1. CRPS-1 often affects one or more limbs after injury or surgery to the area, but it can also occur spontaneously. The mechanisms behind this syndrome are not clear yet, especially since there is no specific nerve damage found to explain the symptoms. The management of CRPS-1 often requires trying different treatments to find out what works best for each individual.
Another challenging type of chronic pain is neuropathic pain. This appears secondary to nerve disease or damage that causes an ongoing transfer of pain signals to the brain. Some examples of neuropathic pain include diabetic neuropathy, caused by long-standing high blood sugar levels; trigeminal neuralgia, a type of facial pain; and some types of cancer pain. Neuropathic pain doesn’t respond to common painkillers and often requires complex treatments.
Traditional painkillers such as paracetamol are not likely to help much with controlling challenging types of chronic pain. Stronger traditional painkillers, such as opioids, can be used temporarily, but they eventually lead to problems such as drug dependence. Antidepressants and anti-epileptic medications are often used to control chronic pain, but they also come with limitations and side effects. When all these fail to work, pain experts sometimes use more specialised treatments, including ketamine treatment.
Ketamine is a drug that was initially used in anaesthesia, but since the 1990s it has also been used in a much lower dose as a treatment for acute and chronic pain. It is not only helpful in the management of persistent chronic pain, but also works as an antidepressant – often used by psychiatrists for treating patients with persistent depression.
Professor Albert Dahan and his colleagues at the Leiden University Medical Center have been studying this versatile drug for over 20 years. Dahan and his team have managed to unlock some of ketamine’s previously unknown mechanisms of action against pain, its psychedelic effects, and also new actions on the heart and breathing mechanism.
To further investigate ketamine’s potential, the team conducted a study involving 60 patients with CRPS-1. Half of the participants were given a 100-hour intravenous infusion of low-dose ketamine, and the other half were given a placebo. Ketamine’s pain relief effect was evaluated by recording the participants’ pain scores, from 0–10, during a 12-week period. The study revealed that the pain scores of the patients who received ketamine were lower compared to those who had the placebo, with the lowest average scores recorded at the end of week 1. Towards the end of the 12-month period, there was no significant difference in the pain scores between the two groups.
The team’s next study of the drug involved an analysis technique called PKPD modelling, a combination of pharmacokinetics and pharmacodynamics. The team took blood samples from patients to measure ketamine levels against pain levels. The researchers were surprised to discover that ketamine’s pain relief effect lasted for 50 days after the termination of treatment. They concluded that ketamine must have initiated an avalanche of events that desensitised pain receptors in the brain and interrupted the vicious circle of chronic pain, an effect that persisted even when ketamine molecules were no longer there.
To better understand ketamine’s pain-relieving effects in the brain, Dahan’s team decided to look into the brain activity of healthy people. They designed a study involving 12 healthy volunteers who received either ketamine or a placebo. Their scores for pain and side effects were recorded, and participants then underwent a functional Magnetic Resonance Imaging scan of their brain, a real-time investigation that reveals the activated areas of the brain. The changes observed in the scans and in relation to pain scores confirmed ketamine’s effect on the areas of the brain that are responsible for pain perception. It also appeared that ketamine changed the connections in the areas inside the brain that deal with so-called self-regulating endogenous pain modulation, a type of pain relief that originates inside the brain and subdues external stimuli at the level of the spinal cord.
When it comes to managing neuropathic pain with ketamine, there is little knowledge based on studying humans. To obtain a better understanding of these actions, the researchers reviewed over 30 studies performed on animals. More specifically, they looked into ketamine’s effect on relieving allodynia, a sensitivity to stimuli that would normally not cause pain. The conclusion was that ketamine successfully relieved allodynia when given for a long time, an effect lasting several days after the treatment.
The mechanism through which ketamine works is best described by the term ‘psychoplastic’, since it works by rewiring certain connections in the brain in a beneficial way, unleashing the healing properties of ketamine.
Dahan’s team conducted another study on healthy volunteers who were given ketamine infusions. The researchers measured changes in the perception of reality in correlation to the participants’ tolerance of pressure pain and the corresponding levels of ketamine in their blood. The results revealed a connection between ketamine’s pain-relieving effect and dissociation, the involuntary detachment from physical reality. Moreover, some also received nitric oxide, a messenger molecule that among other functions also regulates the pathway through which ketamine rewires the brain, while the rest were given a placebo. The team concluded that reduced nitric oxide levels in fact amplify ketamine-induced psychedelic symptoms.
Ketamine’s effects on the human body are not restricted to brain-altering actions. Dahan and his team also considered ketamine’s effects on respiratory and heart function. It is well known that opioids, a category of strong painkillers also called narcotics, can suppress breathing – sometimes putting patients’ lives in danger. To test ketamine’s potential for reversal of this side effect, the team tested 12 volunteers who were given ketamine or a placebo, on top of an opioid called remifentanil. Measurements of vital signs, including breathing, and the levels of the medications in their blood circulation, were taken and analysed. The results confirmed that ketamine can reverse opioid-induced respiratory depression.
The team also tested ketamine’s effects on the heart’s potential to pump blood and the levels of stress caused by the medicine by designing two further studies. In one they measured the volume of blood pumped by the heart in relation to the blood levels of ketamine, and in the other they recorded the levels of the stress hormone, cortisol. The results of their experiments revealed that ketamine increases both the heart’s pumping capacity and helps regulate the stress system.
Ketamine is a versatile medication that has been long used as an anaesthetic and, over the past couple of decades, also as a potent treatment against difficult-to-manage types of chronic pain and depression. Besides further advancing the knowledge on its pain-relieving and brain-rewiring mechanisms, Dahan and his team have extended their studies, including its role in reversing opioid-induced respiratory depression and its effects on heart function and regulation of stress levels. These discoveries open a window for new research that can further establish the use of ketamine in treating mental disorders and also find its role in regulating critical physiological functions.
That’s all for this episode – thanks for listening, and stay subscribed to Research Pod for more of the latest science. Read more about the work of Professor Albert Dahan and his colleagues in the show notes below. See you again soon.
Leave a Reply